Annals of Neurology · 2017 · 21 citations · 30 references
Life SciencesGeneticsPediatricsHuman GeneticsMedical GeneticsPediatric GeneticsGenetic Disease PathologyGenetic DisordersGenetic SyndromesLysosomal Storage DisordersMutation AnalysisDisease Course PredictionDisease-modifying Therapy DevelopmentGenotype-phenotype AssociationsGenotype-phenotype ScreeningInherited Disease DiagnosisMissense MutationsPhenotype-genotype CorrelationPoint Mutation Analysis
OBJECTIVE: Mucopolysaccharidosis IIIA or Sanfilippo disease type A is a progressive neurodegenerative disorder presenting in early childhood, caused by an inherited deficiency of the lysosomal hydrolase sulfamidase. New missense mutations, for which genotype-phenotype correlations are currently unknown, are frequently reported, hampering early prediction of phenotypic severity and efficacy assessment of new disease-modifying treatments. We aimed to design a method to determine phenotypic severity early in the disease course. METHODS: Fifty-three patients were included for whom skin fibroblasts and data on disease course and mutation analysis were available. Patients were phenotypically characterized on clinical data as rapidly progressing or slowly progressing. Sulfamidase activity was measured in fibroblasts cultured at 37 °C and at 30 °C. RESULTS: Sulfamidase activity in fibroblasts from patients homozygous or compound heterozygous for a combination of known severe mutations remained below the limit of quantification under both culture conditions. In contrast, sulfamidase activity in fibroblasts from patients homozygous or compound heterozygous for a known mild mutation increased above the limit of quantification when cultured at 30 °C. With division on the basis of the patients' phenotype, fibroblasts from slowly progressing patients could be separated from rapidly progressing patients by increase in sulfamidase activity when cultured at 30 °C (p < 0.001, sensitivity = 96%, specificity = 93%). INTERPRETATION: Phenotypic severity strongly correlates with the potential to increase sulfamidase activity in fibroblasts cultured at 30 °C, allowing reliable distinction between patients with rapidly progressing or slowly progressing phenotypes. This method may provide an essential tool for assessment of treatment effects and for health care and life planning decisions. Ann Neurol 2017;82:686-696.
30
Measurement of protein using bicinchoninic acid
Pam Smith, Randall I. Krohn, Greg T. Hermanson et al. · Analytical Biochemistry · 1985 · 18.4K citations
A new collection method for the evaluation of nasal mucus proteins
L. Ruocco, Fattori, Romanelli et al. · Clinical & Experimental Allergy · 1998 · 1.3K citations
The frequency of lysosomal storage diseases in The Netherlands
Ben J. H. M. Poorthuis, Ron A. Wevers, Wim J. Kleijer et al. · Human Genetics · 1999 · 725 citations
Marc Tardieu, Michel Zérah, B. Husson et al. · Human Gene Therapy · 2014 · 270 citations
Medicine, Neurology, Pediatrics +17